Oncolytic HSV and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells.

被引：0
|
作者：
Wang, Lei [1 ]
机构：
[1] Wuhan Univ, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e16503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16503
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs
    Mehrpouri, Mahdieh
    Momeny, Majid
    Bashash, Davood
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2022, 42 (01) : 100 - 108
  • [42] PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models
    Van Swearingen, Amanda E. D.
    Siegel, Marni B.
    Bash, Ryan
    Golitz, Brian
    Santos, Charlene
    Darr, David
    Parker, Joel
    Johnson, Gary L.
    Miller, C. Ryan
    Anders, Carey K.
    CANCER RESEARCH, 2014, 74 (19)
  • [43] Co-targeting toll-like receptor and PI3K survival signaling pathways in stem-like castration resistant prostate cancer cells
    Oseni, Saheed Oluwasina
    Branly, Rolando
    Pavlovic, Mirjana
    Kumi-Diaka, James
    CANCER RESEARCH, 2018, 78 (13)
  • [44] Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).
    Armstrong, Andrew J.
    Halabi, Susan
    Healy, Patrick
    Alumkal, Joshi J.
    Yu, Evan Y.
    Winters, Carolyn
    Hobbs, Carey
    Soleau, Colleen
    Slottke, Rachel
    Mundy, Kelly
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance
    Safaroghli-Azar, Ava
    Bashash, Davood
    Kazemi, Alireza
    Pourbagheri-Sigaroodi, Atieh
    Momeny, Majid
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 842 : 89 - 98
  • [46] Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines
    Tosi, Diego
    Atis, Salima
    Mollevi, Caroline
    Martineau, Pierre
    Gongora, Celine
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines
    Tosi, Diego
    Atis, Salima
    Mollevi, Caroline
    Vie, Nadia
    Martineau, Pierre
    Gongora, Celine
    CLINICAL CANCER RESEARCH, 2015, 21
  • [48] A novel, highly potent PI3Kα covalent inhibitor deconvolutes class I PI3K isoforms in cancer cells.
    Keles, Erhan
    Borsari, Chiara
    Sriramaratnam, Rohitha
    Schafer, Thorsten
    Wymann, Matthias P.
    CANCER RESEARCH, 2021, 81 (13)
  • [49] NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
    Park, Eunju
    Park, Jinah
    Han, Sae-Won
    Im, Seock-Ah
    Kim, Tae-You
    Oh, Do-Youn
    Bang, Yung-Jue
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (04) : 1259 - 1266
  • [50] Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
    Matas-Cespedes, Alba
    Rodriguez, Vanina
    Kalko, Susana G.
    Vidal-Crespo, Anna
    Rosich, Laia
    Casserras, Teresa
    Balsas, Patricia
    Villamor, Neus
    Gine, Eva
    Campo, Elias
    Roue, Gael
    Lopez-Guillermo, Armando
    Colomer, Dolors
    Perez-Galan, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3458 - 3471
12345